4WOT
ROCK2 IN COMPLEX WITH 1426382-07-1
Summary for 4WOT
| Entry DOI | 10.2210/pdb4wot/pdb |
| Descriptor | Rho-associated protein kinase 2, methyl 3-[({2'-(aminomethyl)-5'-[(3-fluoropyridin-4-yl)carbamoyl]biphenyl-3-yl}carbonyl)amino]-4-fluorobenzoate (3 entities in total) |
| Functional Keywords | transferase |
| Biological source | Homo sapiens (Human) |
| Cellular location | Cytoplasm: O75116 |
| Total number of polymer chains | 4 |
| Total formula weight | 183952.89 |
| Authors | Augustin, M.,Krapp, S.,Boland, S.,Defert, O.,Bourin, A.,Alen, J.,Leysen, D. (deposition date: 2014-10-16, release date: 2015-05-06, Last modification date: 2024-05-08) |
| Primary citation | Boland, S.,Bourin, A.,Alen, J.,Geraets, J.,Schroeders, P.,Castermans, K.,Kindt, N.,Boumans, N.,Panitti, L.,Fransen, S.,Vanormelingen, J.,Stassen, J.M.,Leysen, D.,Defert, O. Design, synthesis, and biological evaluation of novel, highly active soft ROCK inhibitors. J. Med. Chem., 58:4309-4324, 2015 Cited by PubMed Abstract: ROCK1 and ROCK2 play important roles in numerous cellular functions, including smooth muscle cell contraction, cell proliferation, adhesion, and migration. Consequently, ROCK inhibitors are of interest for treating multiple indications including cardiovascular diseases, inflammatory and autoimmune diseases, lung diseases, and eye diseases. However, systemic inhibition of ROCK is expected to result in significant side effects. Strategies allowing reduced systemic exposure are therefore of interest. In a continuing effort toward identification of ROCK inhibitors, we here report the design, synthesis, and evaluation of novel soft ROCK inhibitors displaying an ester function allowing their rapid inactivation in the systemic circulation. Those compounds display subnanomolar activity against ROCK and strong differences of functional activity between parent compounds and expected metabolites. The binding mode of a representative compound was determined experimentally in a single-crystal X-ray diffraction study. Enzymes responsible for inactivation of these compounds once they enter systemic circulation are also discussed. PubMed: 25898023DOI: 10.1021/acs.jmedchem.5b00308 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.93 Å) |
Structure validation
Download full validation report






